What is L-Carnitine?
L-Carnitine is an endogenous amino acid derivative that shuttles fatty acids into the mitochondria, where they are burned for energy. In research and fitness contexts the injectable form is used for fat metabolism and endurance.
This information is for research and educational purposes only. No medical advice.
Comparison
L-carnitine alone and in blends
Components according to the TPD lexicon. MIC stands for methionine, inositol and choline. Tap a card to open its entry.
Simplified: the amounts per component differ. More components do not automatically mean more effect.
How it works
Without carnitine, long-chain fatty acids cannot cross the inner mitochondrial membrane. L-Carnitine is the shuttle for that - more available carnitine can support fatty acid oxidation. Injected, it bypasses the limited oral uptake.
Where it acts
Where L-carnitine acts
Tap a point or a card. Values from human studies, mostly swallowed.
- Skeletal muscle
21 percent more carnitine after 24 weeks, less glycogen use during light exercise1
L-carnitine - Fat tissue
No fat gain in 12 weeks, the control group gained 1.8 kg of fat2
L-carnitine - Heart muscle
Heart and skeletal muscle form the carnitine store that fills most slowly3
L-carnitine - Kidney
Recovers most carnitine, any excess goes into the urine3
L-carnitine - Gut
When swallowed as a supplement only 5 to 18 percent is absorbed3
L-carnitine
Targets in the ChEMBL database9
Compound Levocarnitin (CHEMBL1149): three recorded mechanisms, type of action on each card.
- Gene
- SLC22A5
- UniProt
- O76082
- ChEMBL
- CHEMBL2073693
- Action
- Transporter, brings carnitine into the cell together with sodium
- Gene
- CPT1B
- UniProt
- Q92523
- ChEMBL
- CHEMBL2216739
- Action
- Enzyme, attaches long-chain fatty acids to carnitine so they can enter the mitochondria
- Gene
- CPT2
- UniProt
- P23786
- ChEMBL
- CHEMBL3238
- Action
- Enzyme in the mitochondria, releases the fatty acid from carnitine again for burning
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
Wall et al. (J Physiol, 2011) showed that chronic L-carnitine intake together with carbohydrate raises muscle carnitine content and alters muscle metabolism during exercise - less glycogen use at moderate intensity. Data on pure fat-loss effects in humans are mixed.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Muscle metabolism after 24 weeks1
Change in percent, 14 healthy men
Carnitine was swallowed here together with carbohydrate meant to raise insulin. All effects only appeared after 24 weeks. There is no such study with injection under the skin.
Weight and fat after 12 weeks2
Change in kg, 6 men per group
In the carnitine group muscle carnitine rose by 20 percent and energy expenditure by 6 percent. The control group got the carbohydrate only and gained weight from it. Very small study.
Research status
Where the research stands
Registered trials in which L-carnitine was given by injection or infusion. Most concern dialysis, the heart and intensive care. As of 26 Oct 2026. 7
- Preclinical Endogenous substance, uptake and excretion well described
- Phase 1 no registered trial
- Phase 2 2 trials, 0 completed, 1 stopped early
- Phase 3 6 trials, 4 completed, 1 stopped early
- Approval since 1985 (levocarnitine)
Show all 14 trials on a timelineHide timeline
NCT03564678 · 10 participants, started May 2018, stopped early Oct 2024. Tests several agents.
NCT06564909 · 76 participants (planned), started Jun 2025, primary endpoint planned Dec 2026.
NCT01107730 · 33 participants, started Apr 2010, primary endpoint reached Apr 2015. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT01580553 · 268 participants, started Jan 2011, primary endpoint reached Mar 2012.
Registry entry ↗ · Results not yet in PubMed
NCT01783041 · 144 participants, started Jan 2013, primary endpoint reached Dec 2020.
Registry entry ↗ · Results not yet in PubMed
NCT02664753 · 254 participants, started Mar 2018, stopped early Dec 2024.
NCT05817799 · 83 participants, started Jan 2023, primary endpoint reached Jul 2023.
Registry entry ↗ · Results not yet in PubMed
NCT05602194 · 440 participants (planned), started Aug 2023, primary endpoint planned Sept 2026.
NCT05322447 · 60 participants, started Apr 2022, primary endpoint reached Aug 2022.
Registry entry ↗ · Results not yet in PubMed
NCT05673239 · 1,008 participants, started Jan 2023, primary endpoint reached Jun 2023.
Registry entry ↗ · Results not yet in PubMed
NCT06849115 · 4 participants, started Jul 2024, primary endpoint reached Dec 2024.
Registry entry ↗ · Results not yet in PubMed
NCT00841295 · 53 participants, started Jul 2008, primary endpoint reached Mar 2013.
Registry entry ↗ · Results not yet in PubMed
NCT02322697 · 60 participants, started Aug 2013, primary endpoint reached Oct 2014.
Registry entry ↗ · Results not yet in PubMed
NCT02722902 · 17 participants, started May 2016, stopped early Jun 2017.
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026, grey = stopped early.
Side effects
- Overall very well tolerated.
- Occasional fishy body odor at high doses (TMAO formation).
- Mild gastrointestinal discomfort possible.
Storage
Store at room temperature, protected from light - no fridge needed. Out of reach of children.